Want to see GB:CRW full AI Analyst Report?
CRW Stock Chart & Stats
1300.00 p
2.00 p(0.15%)
At close: 4:00 PM EDT
1300.00 p
2.00 p(0.15%)
Day’s Range― - ―
52-Week Range988.00 p - 2,644.00 p
Previous CloseN/A
Volume192.74K
Average Volume (3M)71.71K
Market Cap
£440.40M
Enterprise Value637.45M
Total Cash (Recent Filing)£40.96M
Total Debt (Recent Filing)£26.91M
Price to Earnings (P/E)28.1
Beta0.72
Next Earnings
Sep 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.58%
Share Statistics
EPS (TTM)0.63
Shares Outstanding34,237,150
10 Day Avg. Volume64,377
30 Day Avg. Volume71,707
Financial Highlights & Ratios
PEG Ratio0.79
Price to Book (P/B)3.07
Price to Sales (P/S)5.04
P/FCF Ratio17.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£2,600.00Price Target Upside100.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.21
Revenue Forecast (FY)£222.64M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins above 85% indicate a scalable, software-driven cost structure that cushions operating leverage. High product-level profitability supports reinvestment in R&D and sales, enabling durable margin sustainability even with moderate revenue growth.
Conservative Balance SheetVery low leverage provides financial flexibility for multi-year investments, M&A or downturns without pressuring cash flow. A conservative capital structure reduces insolvency risk and preserves the ability to fund product development and customer success programs over time.
Recurring SaaS-like Revenue ModelA subscription and land‑and‑expand commercial model creates high revenue visibility and strong customer retention dynamics. Long switching cycles in healthcare and outcome‑tied value propositions support durable recurring revenue and steady upsell potential.
Bears Say
Declining Free Cash Flow GrowthA meaningful drop in free cash flow growth reduces internal funding for product investment, acquisitions or shareholder returns. If the FCF trend persists, it could pressure strategic flexibility and require either higher margins or external financing to sustain growth initiatives.
Modest Net Profitability / Low ROEModest net margins and weak ROE signal limited conversion of operating efficiency into shareholder returns. Over the medium term this can impede capital allocation, reduce free cash generation per dollar of equity, and limit attractiveness for equity investors seeking durable returns.
Slow Revenue GrowthLow single‑digit top-line growth constrains scale benefits and makes margin expansion the primary path to earnings growth. In a competitive healthcare IT market, subpar revenue momentum increases reliance on cross‑sell and price improvement rather than broad market share gains.
Craneware News
CRW FAQ
What was Craneware Plc’s price range in the past 12 months?
Craneware Plc lowest share price was 988.00 p and its highest was 2644.00 p in the past 12 months.
What is Craneware Plc’s market cap?
Craneware Plc’s market cap is £440.40M.
When is Craneware Plc’s upcoming earnings report date?
Craneware Plc’s upcoming earnings report date is Sep 22, 2026 which is in 28 days.
How were Craneware Plc’s earnings last quarter?
Craneware Plc released its earnings results on Mar 02, 2026. The company reported 0.427 p earnings per share for the quarter, beating the consensus estimate of N/A by 0.427 p.
Is Craneware Plc overvalued?
According to Wall Street analysts Craneware Plc’s price is currently Undervalued.
Does Craneware Plc pay dividends?
Craneware Plc pays a Semiannually dividend of 15 p which represents an annual dividend yield of 2.58%. See more information on Craneware Plc dividends here
What is Craneware Plc’s EPS estimate?
Craneware Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Craneware Plc have?
Craneware Plc has 34,237,150 shares outstanding.
What happened to Craneware Plc’s price movement after its last earnings report?
Craneware Plc reported an EPS of 0.427 p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.99%.
Which hedge fund is a major shareholder of Craneware Plc?
Currently, no hedge funds are holding shares in GB:CRW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Craneware Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
£2,600.00 (100.00% Upside)
£2,600.00 (100.00% Upside)
Insider Transactions
Bought Shares
Worth £107.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.04%
12-Months-Change
Fundamentals
Return on Equity
2.58%
Trailing 12-Months
Asset Growth
-13.53%
Trailing 12-Months
Company Description
Craneware Plc
Craneware plc, with its associated entities, is dedicated to creating, distributing, and maintaining cutting-edge software applications tailored for the U.S. healthcare industry. Its extensive suite of products is designed to streamline and improve a wide array of operational functions for healthcare organizations. Among its flagship offerings is the Chargemaster Toolkit, an automated, cloud-hosted platform for charge master administration, crucial for enabling providers to achieve optimal and legitimate revenue reimbursement. Trisus Supply facilitates the identification and resolution of data inconsistencies between disparate systems. The Physician Revenue Toolkit, a Software-as-a-Service (SaaS) solution, empowers the oversight of physician group performance indicators, billing rates, procedural codes, relative value units, and fee schedules. Complementing these are Reference Plus, another SaaS tool for comprehensive chargemaster analytics, and Pharmacy ChargeLink, engineered to bolster charge capture, pricing strategies, and cost control within pharmacy operations. Furthermore, the company offers integration software that autonomously uploads chargemaster modifications to patient billing systems, thereby ensuring billing precision. The Trisus Pricing Analyzer, a SaaS application, streamlines the pricing model development process. Extending its capabilities, Craneware delivers tools for regulatory adherence and financial oversight: InSight Medical Necessity, a SaaS solution for validating the medical necessity required by U.S. payers and for creating advance beneficiary notices; Trisus Claims Informatics, a program that automates the review of claims and coding; and InSight Audit, a browser-based audit management application for healthcare entities to handle governmental and commercial examinations. Additionally, the firm presents Trisus Healthcare Intelligence, a platform for cost analysis and resource optimization; solutions for pricing transparency; and InSight Denials, which facilitates the analysis, tracking, trending, and reporting of denial data, further supported by appeals management services. Beyond its software offerings, Craneware provides comprehensive client success management, specialized consulting, and an array of professional services. The organization also oversees its own sales, marketing efforts, and continuous product and software innovation. Founded in 1999, Craneware plc has its corporate headquarters situated in Edinburgh, United Kingdom.
CRW Stock 12 Month Forecast
Average Price Target
2,600.00 p
▲(100.00% Upside)